Department of Neurology, Hospital South West Jutland, University Hospital of Southern Denmark, Esbjerg, Denmark.
BRIDGE, Brain Research - Inter-Disciplinary Guided Excellence, Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark.
Neurodegener Dis Manag. 2020 Oct;10(5):267-276. doi: 10.2217/nmt-2020-0025. Epub 2020 Jul 20.
Diroximel fumarate (DRF) is a new emerging therapy for patients with multiple sclerosis. The levels of its active metabolite, monomethyl fumarate, are bioequivalent to the levels generated from dimethyl fumarate (DMF) treatment. The efficacy and safety profiles of DRF are expected to be similar to the well-established profiles of DMF. The metabolism of DRF leads to lower concentration of methanol in the small intestine than with DMF and thus reduced severity and frequency of gastrointestinal adverse events. DRF seems a promising alternative to DMF and other first-line therapies for multiple sclerosis. The current review is based on the two existing Phase III trials of DRF: the interim analysis of the EVOLVE-MS-1 trial and the completed EVOLVE-MS-2 trial.
富马酸二甲酯（DMF）是一种新出现的多发性硬化症治疗药物。其活性代谢物单甲基富马酸的水平与来自 DMF 治疗的水平生物等效。DRF 的疗效和安全性概况预计与 DMF 的既定概况相似。DRF 的代谢导致小肠中甲醇的浓度低于 DMF，从而降低胃肠道不良事件的严重程度和频率。DRF 似乎是 DMF 和其他多发性硬化症一线治疗的有前途的替代品。本综述基于 DRF 的两项现有 III 期试验：EVOLVE-MS-1 试验的中期分析和已完成的 EVOLVE-MS-2 试验。
